Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1

Heterologous prime-boost immunization strategies can evoke powerful T cell immune responses and may be of value in developing an improved tuberculosis vaccine. We show that recombinant modified vaccinia virus Ankara, expressing Mycobacterium tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guérin (BCG)-induced Ag 85A specific CD4+ and CD8+ T cell responses in mice. A comparison of intranasal (i.n.) and parenteral immunization of BCG showed that while both routes elicited comparable T cell responses in the spleen, only i.n. delivery elicited specific T cell responses in the lung lymph nodes, and these responses were further boosted by i.n. delivery of M.85A. Following aerosol challenge with M. tuberculosis, i.n. boosting of BCG with either BCG or M.85A afforded unprecedented levels of protection in both the lungs (2.5 log) and spleens (1.5 log) compared with naive controls. Protection in the lung correlated with the induction of Ag 85A-specific, IFN-γ-secreting T cells in lung lymph nodes. These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis.

[1]  W. Busey,et al.  Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. , 2015, The American review of respiratory disease.

[2]  C. Dascher,et al.  Dissemination of Mycobacterium tuberculosis Is Influenced by Host Factors and Precedes the Initiation of T-Cell Immunity , 2002, Infection and Immunity.

[3]  A. Bean,et al.  Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of Prior Mycobacterium bovis BCG Immunization , 2002, Infection and Immunity.

[4]  H. McShane,et al.  Protective Immunity against Mycobacterium tuberculosis Induced by Dendritic Cells Pulsed with both CD8+- and CD4+-T-Cell Epitopes from Antigen 85A , 2002, Infection and Immunity.

[5]  L. Fiette,et al.  Dendritic Cells Are Host Cells for Mycobacteria In Vivo That Trigger Innate and Acquired Immunity1 , 2002, Journal of Immunology.

[6]  M. Castrucci,et al.  The Role of Antigen in the Localization of Naive, Acutely Activated, and Memory CD8+ T Cells to the Lung During Influenza Pneumonia1 , 2001, The Journal of Immunology.

[7]  I. M. Belyakov,et al.  Strategies for designing and optimizing new generation vaccines , 2001, Nature Reviews Immunology.

[8]  N. Krug,et al.  Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system , 2001, The Anatomical record.

[9]  A. Thomas,et al.  Divergent effect of bacillus Calmette–Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. H. van der Kwast,et al.  Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. , 2001, Vaccine.

[11]  B. Rouse,et al.  Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules1 , 2001, The Journal of Immunology.

[12]  G. Sutter,et al.  Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. , 2001, Vaccine.

[13]  S. Behar,et al.  Gamma Interferon-Producing CD4+ T Lymphocytes in the Lung Correlate with Resistance to Infection withMycobacterium tuberculosis , 2001, Infection and Immunity.

[14]  I. Orme,et al.  Boosting Vaccine for Tuberculosis , 2001, Infection and Immunity.

[15]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Döffinger,et al.  Human interferon‐g‐mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion , 2000, Immunological reviews.

[17]  H. Dockrell,et al.  Human CD8+ T Cells Specific forMycobacterium tuberculosis Secreted Antigens in Tuberculosis Patients and Healthy BCG-Vaccinated Controls in The Gambia , 2000, Infection and Immunity.

[18]  P. Andersen,et al.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.

[19]  Jun Wang,et al.  Genetically Determined Disparate Innate and Adaptive Cell-Mediated Immune Responses to Pulmonary Mycobacterium bovis BCG Infection in C57BL/6 and BALB/c Mice , 2000, Infection and Immunity.

[20]  A. Apt,et al.  Comparative Analysis of T Lymphocytes Recovered from the Lungs of Mice Genetically Susceptible, Resistant, and Hyperresistant to Mycobacterium tuberculosis-Triggered Disease1 , 2000, The Journal of Immunology.

[21]  Gerhard Walzl,et al.  Influenza Virus Lung Infection Protects from Respiratory Syncytial Virus–Induced Immunopathology , 2000, The Journal of experimental medicine.

[22]  J. Ramírez,et al.  Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.

[23]  B. Moss,et al.  Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. , 1999, Vaccine.

[24]  J. Flynn,et al.  Early Emergence of CD8+ T Cells Primed for Production of Type 1 Cytokines in the Lungs of Mycobacterium tuberculosis-Infected Mice , 1999, Infection and Immunity.

[25]  M. Horwitz,et al.  T-Cell Epitope Mapping of the Three Most Abundant Extracellular Proteins of Mycobacterium tuberculosis in Outbred Guinea Pigs , 1999, Infection and Immunity.

[26]  J. Berzofsky,et al.  Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Wang,et al.  Macrophages are a significant source of type 1 cytokines during mycobacterial infection. , 1999, The Journal of clinical investigation.

[28]  J. Altman,et al.  Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[30]  J. Ulmer,et al.  Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+ and CD8+T-Cell Epitopic Repertoire Broader than That Stimulated byMycobacterium tuberculosis H37Rv Infection , 1998, Infection and Immunity.

[31]  A. McMichael,et al.  Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. , 1998, Vaccine.

[32]  J. Sterne,et al.  Does the efficacy of BCG decline with time since vaccination? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[33]  W. Rom,et al.  Local immune responses correlate with presentation and outcome in tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[34]  H. Dockrell,et al.  Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Braden,et al.  The epidemiology of tuberculosis in the United States. , 1997, Clinics in chest medicine.

[36]  R. Phillpotts,et al.  A simple device for the exposure of animals to infectious microorganisms by the airborne route , 1997, Epidemiology and Infection.

[37]  K. Rosenthal,et al.  Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization , 1996, The Journal of experimental medicine.

[38]  B. Moss,et al.  Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. , 1996, Vaccine.

[39]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[40]  M. Horwitz,et al.  Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis , 1996, Infection and immunity.

[41]  N. Maine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi , 1996, The Lancet.

[42]  P. Fine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. , 1996, Lancet.

[43]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[44]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[45]  M. Gheorghiu.  BCG-induced mucosal immune responses. , 1994, International journal of immunopharmacology.

[46]  D. Snider,et al.  Epidemiology of tuberculosis in the United States. , 1989, Epidemiologic reviews.

[47]  H. Wiker,et al.  Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. , 1987, Microbial pathogenesis.

[48]  J. Jernigan,et al.  Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study. , 1975, Journal of the National Cancer Institute.

[49]  C. Meyer,et al.  Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study , 1975, Cancer.

[50]  H. Stickl.  Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". , 1974, Preventive medicine.

[51]  S. Rosenthal,et al.  Aerogenic BCG vaccination against tuberculosis in animal and human subjects. , 1968, The Journal of asthma research.

[52]  I. Orme,et al.  Temporal and Spatial Arrangement of Lymphocytes within Lung Granulomas Induced by Aerosol Infection with Mycobacterium tuberculosis , 2001 .

[53]  Malin,et al.  Human cytolytic and interferon g-secreting CD 8 1 T lymphocytes specific for Mycobacterium tuberculosis , 1997 .

[54]  J. Grange,et al.  Guidelines for speciation within the mycobacterium tuberculosis complex , 1996 .